The company and the board of directors confirm the authenticity, accuracy, and completeness of the information disclosed in this announcement, without any false statements or misleading omissions.
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") held the 19th meeting of the 7th Board of Directors on June 2, 2026, and approved the proposal regarding the adjustment of the exercise price of the 2021 stock option incentive plan, which is as follows:
- Relevant Review Procedures
On June 18, 2021, the Company convened the 7th meeting of the 6th Board of Directors, which reviewed and approved the "Proposal on the 2021 Stock Option Incentive Plan (Draft)" and its summary. The board proposed to authorize the chairman to handle matters related to the 2021 stock option incentive plan.
On June 18, 2021, the Company convened the 7th meeting of the 6th Board of Supervisors, which reviewed and approved the "Proposal on the 2021 Stock Option Incentive Plan (Draft)" and its summary.
From June 21 to July 1, 2021, the Company conducted the first adjustment of the stock options.